Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSPPC-96 immunotherapy in newly diagnosed glioblastoma
NCT02122822Phase 1Completed
- Sponsor
- Cure & Sure Biotech
- Start
- Jul 2013
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vitespen in glioblastoma (GBM), sponsored by Cure & Sure Biotech. Primary endpoints: blood count, blood chemistries and 2 more. Started Jul 2013; status: completed.
02
Drugs
vitespen
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02122822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122822.